Boehringer, Lilly’s Jardiance meets primary endpoint in EMPA-KIDNEY trial
EMPA-KIDNEY is a randomised, double-blind, placebo-controlled clinical trial that studied the effect of Jardiance (empagliflozin) on progression of…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
07 Nov 22
EMPA-KIDNEY is a randomised, double-blind, placebo-controlled clinical trial that studied the effect of Jardiance (empagliflozin) on progression of…